STADA UK Respiratory

Proxor^® (beclometasone/formoterol) indications

For use in adults only.

Asthma

Proxor^® 100/6 and 200/6: Regular treatment of asthma where use of a combination product is appropriate: Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β₂-agonist; Patients already adequately controlled on both inhaled corticosteroids and long-acting β₂-agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Proxor^® 100/6: Symptomatic treatment of severe COPD (FEV₁ 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Proxor^® 100/6 is licensed for Maintenance and Reliever Therapy (MART) in asthma.

Trokide^® (tiotropium bromide) indications

Trokide Vertical-Haler^® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Fixkoh^® (salmeterol/fluticasone) indications

Fixkoh Airmaster^® is indicated in adults and adolescents 12 years of age and older.

Asthma

In the regular treatment of asthma where use of a combination product (long-acting β₂ agonist and inhaled corticosteroid is appropriate. In patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonist, or, patients already adequately controlled on both inhaled corticosteroid and long-acting β₂ agonist. Note: Fixkoh Airmaster^® 50 microgram/100 micrograms is not appropriate in adults and children with severe asthma.

Chronic Obstructive Pulmonary Disease (COPD)

For the symptomatic treatment of patients with COPD, with a FEV₁ < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.